Topical interferon alfa-2b for primary treatment of conjunctiva-cornea intraepithelial neoplasia
Keywords:
Interferón alfa-2b tópico. Neoplasia intraepitelial conjuntivo- corneal.Abstract
We describe two cases of conjunctival-cornea intraepithelial neoplasia (CIN), treated with topical IFN alfa 2b. The traditional treatment for CIN is surgical excision usually with adjunctive cryotherapy. However, residual tumour may remain, which can lead to recurrence rates of more than 50%. 5-Fluorouracil, mitomicyn C and interferon α 2b are new pharmacological agents that have proved their efficacy in the treatment of CIN. As side effects are common, we present IFN α 2b as a single therapeutic agent as an effective and optimal treatment for presumed recurrent corneal and conjunctival intraepithelial neoplasia. It offers the benefits of topical therapy and avoids the risks of surgical or other interventions – specifically, ocular surface toxicity, cicatricial conjunctival changes, and limbal stem cell deficiency.Downloads
References
1. LEE GA, WILLIAMS G, HIRST LW, GREEN AC. Risk factors in the development of ocular surface epithelial dysplasia. Ophthalmology 1994; 101: 360-364.
https://doi.org/10.1016/S0161-6420(94)31328-5
2. WILSON MW, HUNGERFORD JL, GEORGE SM, MADREPERLA SA. Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. Am J Ophthalmol 1997; 124: 303-311.
https://doi.org/10.1016/S0002-9394(14)70822-0
3. VANN RR, KARP CL. Perilesional and topical interferon alfa- 2b for conjunctival and corneal neoplasia. Ophthalmology 1999; 106: 91-97.
https://doi.org/10.1016/S0161-6420(99)90009-X
4. SHIELDS JA, SHIELDS CL, DE POTTER P. Surgical management of conjunctival tumors. The 1994 Lynn B. Mc Mahan Lecture. Arch Ophthalmol 1997; 115: 808-815.
https://doi.org/10.1001/archopht.1997.01100150810025
5. YEATTS RP, ENGELBRECHT NE, CURRY CD, FORD JG, WALTER KA. 5- Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology 2000; 107: 2190-2195.
https://doi.org/10.1016/S0161-6420(00)00389-4
6. BARON S, TYRING SK, FLEISCHMANN WR, COPPENHAVER DH, NIESSEL DW, KLIMPEL GR et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266: 1375-1383.
https://doi.org/10.1001/jama.1991.03470100067035
7. MASKIN SL. Regression of limbal epithelial dysplasia ith topical interferon. Arch Ophthalmol 1994; 112:1145-1146.
https://doi.org/10.1001/archopht.1994.01090210029007
8. TOLEDANO FERNÁNDEZ N, GARCÍA SÁENZ S, DÍAZ VALLE D, ARTEAGA SÁNCHEZ A, SEGURA BEDMAR M, LORENZO GIMÉNEZ S et al. Interferon alfa- 2b treatment in selected cases of recurrent conjunctival intraepithelial neoplasia. Arch Soc Esp Oftalmol 2003; 78: 265-271.
https://doi.org/10.4321/S0365-66912003000500006
9. KARP CL, MOORE JK, ROSA RH. Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon a-2b. Ophthalmology 2001;108:1093-1098.
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
